BMEA — Biomea Fusion Share News
0.000.00%
Last trade - 00:00Biomea slumps as FDA puts diabetes drug trials on clinical hold
Biomea slumps as US FDA places hold on diabetes trial
U.S. FDA places hold on Biomea's diabetes trial (updated)
U.S. FDA places hold on Biomea's diabetes trial
U.S. STOCKS ON THE MOVE-Paychex, ChampionX, EV stocks
U.S. STOCKS ON THE MOVE-VirTra, GE Vernova, Blackstone
Biomea slips after JP Morgan downgrades to 'neutral,' cuts PT
U.S. STOCKS ON THE MOVE-PVH, Verve Therapeutics, Canoo
U.S. STOCKS ON THE MOVE-PVH Corp, oil companies, health insurers
Biomea slips after JP Morgan downgrades to 'neutral,' cuts PT
U.S. RESEARCH ROUNDUP- Biomea Fusion, BlackRock, Capital Bancorp
Brief: Biomea Fusion Highlights Initial Data From The First Two Type 1 Diabetes Patients Dosed With BMF-219
U.S. STOCKS ON THE MOVE-Adobe, United Parcel Service, ZeroFox Holdings
U.S. STOCKS ON THE MOVE-New York Community Bancorp, Rallybio, Willis Towers Watson
U.S. STOCKS ON THE MOVE-DocuSign, Eli Lilly, Sunworks
Biomea rises after Truist Securities initiates coverage with 'buy'
Brief: Biomea Fusion Top Line Data Of The 200 Mg Dose Cohorts From The Ongoing Phase Ii Clinical Study (Covalent-111)
Brief: Biomea Fusion Announces Bmf-219 Was Generally Well Tolerated, No Dose Reductions, Dose Discontinuations
Brief: Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes